|Cancer Stem Cell News 6.01 January 11, 2017|
Targeting a specific DNA-repairing protein in the brain could be an effective way to treat the most aggressive type of brain tumor, a study suggests. Researchers at the University of Leeds found that inhibiting this protein, called RAD51, helped increase the effectiveness of radiotherapy in killing off glioblastoma cells in the lab. [Press release from the University of Leeds discussing online prepublication in Stem Cell Reports]
The authors investigated the role of the cyclooxygenase-2 (COX-2), a downstream target of TGFβ, in regulating breast cancer stem cells in triple negative breast cancer (TNBC). Bioinformatics analysis revealed that COX-2 is highly expressed in TNBC and that its expression correlated with poor survival outcome in basal subtype of breast cancer. [Sci Rep]
Scientists investigated the effects of netrin-1 on glioblastoma pathogenesis and glioblastoma cell stemness. Netrin-1 activated Notch signaling in glioblastoma cells resulting in subsequent gain of stemness and enhanced invasiveness of these cells. [J Exp Clin Cancer Res]
The objective of this study was to investigate the usefulness of sulforaphane (SFN)–a constituent of cruciferous vegetables with a multitargeted effect–as a therapeutic agent for glioblastoma (GBM). SFN robustly inhibited the growth of GBM cell–induced cell death in established cell cultures and early-passage primary cultures and, most importantly, was effective in eliminating GBM stem cells, which play a major role in drug resistance and disease recurrence. [J Neurosurg]
The functional association of gastric cancer stem cell markers with stemness and epithelial-mesenchymal transition (EMT) signature genes is unclear. Using gene-specific primers, researchers found that the NANOG expression primarily originates from the retrogene NANOGP8. LGR5 over-expression significantly enhanced sphere cell growth, cell proliferation, cell migration and drug resistance in MGC803 cells. [PLoS One]
Camptothecin-induced apoptosis and necrosis in cancer stem cells with and without siCLU treatment were simultaneously measured using Qdot-based total internal reflection fluorescence microscope. [Cell Biol Toxicol]
To improve the anticancer effects of gemcitabine, the authors investigated the molecular mechanism of KMC07 cells’ resistance to gemcitabine. They demonstrated constitutive activation of the Kras-MEK matrix metalloproteinase-10 signaling pathway in KMC07 cells that was enhanced by gemcitabine through histone acetylation. [Pancreas]
The inhibition of the multiple myeloma CD138−CD34− cancer stem cell growth was investigated in non-obese-diabetic/severe-combined-immunodeficiency mice that were implanted with multiple myeloma RPMI 8226 cancer stem cells and treated with the LCL-HHT-H-PEG. [Exp Biol Med (Maywood)]
Investigators demonstrated that miR-134-3p can directly decrease RAB27a expression. Furthermore, overexpression of miR-134-3p can effectively inhibit the proliferation, invasion and tumorigenicity of human ovarian cancer stem cells in vivo and in vitro. [Gene]
Scientists showed that a fraction of cancer stem cells derived from patients with gastric carcinoma and colorectal carcinoma are capable of producing neurons that are involved in tumor neurogenesis and tumor growth. [Signal Transduct Target Ther]
The authors provide an overview of focal adhesion kinase expression and activity in the context of tumor biology, discussing the current evidence of its connection with hepatocellular carcinoma development and progression. [Int J Mol Sci]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Genprex, Inc. announced positive interim data from an ongoing Phase II clinical trial evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor erlotinib for the treatment of late stage non-small cell lung cancer patients. [Genprex, Inc.]
Puma Biotechnology, Inc. has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 as a single agent in patients with solid tumors who have an activating HER2 mutation. [Puma Biotechnology, Inc.]
TARIS Biomedical LLC announced that it has closed initial enrollment in its Phase Ib clinical trial of TAR-200 following highly positive results. [TARIS Biomedical LLC]
OncoMed Pharmaceuticals, Inc. announced dosing of the first patient in a Phase Ib clinical trial of anti-DLL4/VEGF bispecific antibody plus chemotherapy in patients with second-line metastatic colorectal cancer. [OncoMed Pharmaceuticals, Inc. (GlobeNewswire, Inc.)]
The Cleveland Clinic released an apology from a staff physician who published an antivaccination column on the news website Cleveland.com. The doctor, Daniel Neides, will be “appropriately disciplined,” the Ohio hospital added in its own statement, which noted that the family physician’s views do not reflect his institution’s. [ScienceInsider]
A survey of more than 1,000 UK-based university staff suggests that the country’s vote to leave the European Union could drive an academic exodus. [Nature News]
NEW 19th International AEK Cancer Congress
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.